Drug repositioning in the treatment of malaria and TB

Effect of Meropenem against Multidrug-ResistantMycobacterium tuberculosis

(2014) A.Y. Coban et al.   JOURNAL OF CHEMOTHERAPY

A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers

(2011) Roma Chilengi et al.   MALARIA JOURNAL

Update on genetic markers of quinine resistance in Plasmodium falciparum

(2011) John Okombo et al.   MOLECULAR AND BIOCHEMICAL PARASITOLOGY

Antibiotics in Malaria Therapy and their Effect on the Parasite Apicoplast

(2010) G. Pradel et al.   CURRENT MOLECULAR MEDICINE

Drugs in Development for Tuberculosis

(2010) Ann M. Ginsberg   DRUGS

Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives

(2010) Raoni S.B. Gonçalves et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Intermittent preventive treatment against malaria: an update

(2010) Roly D Gosling et al.   Expert Review of Anti-Infective Therapy

The nitroimidazooxazines (PA-824 and analogs): structure–activity relationship and mechanistic studies

(2010) William A Denny et al.   Future Medicinal Chemistry

Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

(2010) Leonard Amaral et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open‐Label Randomized, Controlled Clinical Trial

(2010) Kamala Thriemer et al.   JOURNAL OF INFECTIOUS DISEASES

Global tuberculosis drug development pipeline: the need and the reality

(2010) Zhenkun Ma et al.   LANCET

Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

(2010) Arjen M Dondorp et al.   LANCET

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

(2010) José A Caminero et al.   LANCET INFECTIOUS DISEASES

Conformationally-constrained indeno[2,1-c]quinolines – a new class of anti-mycobacterial agents

(2010) Ram Shankar Upadhayaya et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Synthesis and structure of azole-fused indeno[2,1-c]quinolines and their anti-mycobacterial properties

(2010) Ram Shankar Upadhayaya et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

The evolution, metabolism and functions of the apicoplast

(2010) L. Lim et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

The Global Fight Against HIV/AIDS, Tuberculosis, and Malaria

(2009) Marco Vitoria et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis

(2009) Susan E. Dorman et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis

(2009) Kathy N. Williams et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

In Vitro Activity of Antifolate and Polymorphism in Dihydrofolate Reductase of Plasmodium falciparum Isolates from the Kenyan Coast: Emergence of Parasites with Ile-164-Leu Mutation

(2009) S. M. Kiara et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meropenem-Clavulanate: A New Strategy for the Treatment of Tuberculosis?

(2009) Ulrike Holzgrabe   ChemMedChem

Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive update

(2009) M. Shahid et al.   CRITICAL REVIEWS IN MICROBIOLOGY

Drug repositioning summit: Finding new routes to success

(2009) C. Campàs   DRUG NEWS & PERSPECTIVES

Long-term Methotrexate for Crohnʼs Disease

(2009) Eugeni Domènech et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

(2009) Marcus B Conde et al.   LANCET

Artemisinin Resistance inPlasmodium falciparumMalaria

(2009) Arjen M. Dondorp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosis

(2009) J.-E. Hugonnet et al.   SCIENCE

New anti-tuberculosis agents amongst known drugs

(2009) Kathryn E.A. Lougheed et al.   TUBERCULOSIS

Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis

(2009) Sarah L. Kinnings et al.   PLoS Computational Biology

Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis

(2008) Reynaldo Dietze et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model

(2008) K. N. Williams et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Role of Methotrexate in the Treatment of Chronic Cholestatic Disorders

(2008) Kerri Novak et al.   Clinics in Liver Disease

The Plastid-Like Organelle of Apicomplexan Parasites as Drug Target

(2008) J. Wiesner et al.   CURRENT PHARMACEUTICAL DESIGN

HIV Protease Inhibitors Inhibit the Development of Preerythrocytic-StagePlasmodiumParasites

(2008) Charlotte V. Hobbs et al.   JOURNAL OF INFECTIOUS DISEASES

Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy

(2008) R Matthew Chico et al.   MALARIA JOURNAL

High Risk of Severe Anaemia after Chlorproguanil-Dapsone+Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency

(2008) Caterina I. Fanello et al.   PLoS One

The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis

(2008) S. P. S. Rao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA